Dear Colleagues,

Although rare, ovarian cancer is one of the deadliest gynaecological cancers. In most cases it is detected as an advanced tumor, since early diagnosis is not possible for most forms of the disease. Surgery and platinum-based compounds have been the mainstay of therapy for many years. The prognosis for ovarian cancer depends on the type of surgery and on the response to chemotherapy. Other regimens have little effect if the disease does not respond to platinum. Platinum has been the most common treatment for many years, even though several new therapies are emerging. The role of the BRCA test in deciding whether or not to administer PARP-inhibitors is now becoming increasingly important.

In this collection of articles, we would like to evaluate the efficacy of new medical and surgical therapies in relation to the patient’s BRCA mutational status. This will provide an overview of recent attempts to improve the diagnosis and prognosis of ovarian cancer.

We are particularly interested in new diagnostic and therapeutic strategies or literature reviews that lay out the foundation for these improvements.

Dr.  Anna Myriam Perrone and Dr. Pierandrea De Iaco

Guest Editors